Treatment with pantethine

Journal of Evidence-Based Complementary and Alternative Medicine

Volumn 16, Issue 2, 2011, Pages 21-28

  Horváth, Zoltán ^a   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Atherosclerosis; Coenzyme A; Cysteamine; Dyslipidemia; Lipids; Pantetheine; Pantethine; Pantothenic acid; PKAN; Platelets

Indexed keywords

EID: 79957942836     PISSN: 21565872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Williams WL, Hoff-Jorgensen WE, Snell EE. Determination and properties of an unidentified growth factor required by Lactobacilus bulgaricus. J Biol Chem. 1949;177:933-940.
2. Snell EE, Brown GM. Pantethine and related forms of the Lactobacillus bulgaricus factor. Adv Enzymol Relat Subj Biochem. 1953;14:49-71.
3. Hoagland M, Novelli GD. Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from panthenate. J Biol Chem. 1954;207:767-773.
4. Trumbo PR. Pantothenic acid. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:462-467.
5. Ono S, Kameda K, Abiko Y. Metabolism of pantethine in the rat. J Nutr Sci Vitaminol (Tokyo). 1974;20:203-213.
6. Branca D, Scutari G, Siliprandi N. Pantethine and pantothenate effect on the CoA content of rat liver. Int J Vitam Nutr Res. 1984; 54:211-216.
7. Reibel DK, Wyse BW, Berkich DA, Neely JR. Coenzyme A metabolism in pantothenic acid-deficient rats. J Nutr. 1982;112: 1144-1150.
8. Gropper SS, Smith JL, Groff JL. Advanced Nutrition and Human Metabolism. Belmont, CA: Wadsworth, Cengage Learning; 2009.
9. Otten JJ, Hellwig JP, Meyers LD. Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington, DC: National Academies Press; 2008.
10. Cighetti G, Del Puppo M, Paroni R, Fiorica E, Galli Kienle M. Pan-tethine inhibits cholesterol and fatty acid synthesis and stimulates carbon dioxide formation in isolated rat hepatocytes. J Lipid Res. 1987;28:152-161.
11. Ranganathan S, Jackson RL, Harmony JA. Effect of pantethine on the biosynthesis of cholesterol in human skin fibroblasts. Atherosclerosis. 1982;44:261-273.
12. Cighetti G, Del Puppo M, Paroni R, Galli Kienle M. Modulation of HMG-CoA reductase activity by pantetheine/pantethine. Biochim Biophys Acta. 1988;963:389-393.
13. Bon GB, Cazzolato G, Zago S, Avogaro P. Effects of pantethine on in-vitro peroxidation of low density lipoproteins. Atherosclerosis. 1985;57:99-106.
14. McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med Hypotheses. 2001;56:314-317.
15. Tomikawa M, Nakayasu T, Tawara K, Kameda KY, Abiko Y. Effect of pantethine on lipoprotein profiles and HDL subfractions in experimentally hypercholesterolemic rabbits. Atherosclerosis. 1982;41:267-277.
16. Wittwer CT, Beck S, Peterson M, Davidson R, Wilson RE, Hansen RG. Mild pantothenate deficiency in rats elevates serum triglyceride and free fatty acid levels. J Nutr. 1990;120: 719-725.
17. Farina R, Lovati MR, Raucci G, Sirtori CR. Effects of pantethine on different models of experimental hyperlipidemia in rodents: a comparison with clofibrate. Pharmacol Res Commun. 1982; 14:499-510.
18. Carrara P, Matturri L, Galbussera M, Lovati MR, Franceschini G, Sirtori CR. Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. Atherosclerosis. 1984;53:255-264.
19. Miccoli R, Marchetti P, Sampietro T, et al. Effects of pantethine on lipids and apolipoproteins in hypercholesterolemic diabetic and non-diabetic patients. Curr Ther Res. 1984;36:545-549.
20. McRae MP. Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability. Nutr Res. 2005;25:319-333.
21. Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol. 1986; 24:630-637.
22. Arsenio L, Bodria P, Magnati G, Strata A, Trovato R. Effectiveness of long-term treatment with pantethine in patients with dys-lipidemia. Clin Ther. 1986;8:537-545.
23. Apebe P, Vaccarino V, Sirtori M, et al. Treatment of type III hyperlipiopoteinemia with pantethine partial correction of the biochemical defect. Curr Ther Res. 1987;42:1151-1156.
24. Miccoli R, Marchetti P, Sampietro T, et al. Effects of pan-tethine on lipids and apolipoproteins in hypercholesterolemic diabetic and non-diabetic patients. Curr Ther Res. 1984; 36:545-549.
25. Postiglione A, Rubba P, Cicerano U, Chierchia I, Mancini M. Pantethine versus fenofibrate in the treatment of type II hyperlipo-proteinemia. Monogr Atheroscler. 1985;13:145-148.
26. Cattin L, DaCol P, Fonda M, et al. Treatment of hypercholester-olemia with pantethine and fenofibrate: an open randomized study on 43 subjects. Curr Ther Res. 1985;38:386-395.
27. Agrati AM, Ambrosi G, Ferraro G, et al. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: a controlled study. Curr Ther Res. 1989;45:650-663.
28. Tonutti L, Taboga C, Noacco C. Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia (in Italian). Minerva Med. 1991;82:657-663.
29. Horvath Z, Vecsei L. Current medical aspects of pantethine. Ideg-gyogy Sz. 2009;62:220-229.
30. Shattil SJ, Cooper RA. Membrane microviscosity and human platelet function. Biochemistry. 1976;15:4832-4837.
31. Shastri KM, Carvalho AC, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res. 1980;21:467-472.
32. Prisco D, Rogasi PG, Matucci M, et al. Effect of pantethine treatment on platelet aggregation and thromboxane A2 production. Curr Ther Res. 1984;35:700-706.
33. Prisco D, Rogasi PG, Matucci M, et al. Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyper-lipoproteinemia. Angiology. 1987;38:241-247.
34. Arimori S, Shimizu Y, Komatsuda K, et al. Effects of pan-tethine on ADP-induced aggregation, microviscosity and ultra-microstruture of human platelets. Tokai J Exp Clin Med. 1979; 4:243-252.
35. Hofmann B, Lang A, Ostermann G, et al. Effect of pantethine on platelet functions in vitro. Curr Ther Res. 1987;41:761-801.
36. Hiramatsu K, Nozaki H, Arimori S. Influence of pantethine on platelet volume, microviscosity, lipid composition and functions in diabetes mellitus with hyperlipidemia. Tokai J Exp Clin Med. 1981;6:49-57.
37. Bon GB, Ballerini PF, Pitteri G, et al. In vitro effect of pantethine on platelet aggregation. Curr Ther Res. 1986;40:464-470.
38. Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). Eur J Paediatr Neurol. 2002;6: 243-247.
39. Renaud DL, Kotagal S. Pantothenate-kinase associated neurode-generation (PKAN) "eye of the tiger" sign. Pediatr Neurol. 2007;36:70-71.
40. Rana A, Seinen E, Siudeja K, et al. Pantethine rescues a Drosophila model for pantothenate kinase-associated neurode-generation. Proc Natl Acad Sci USA. 2010;107:6988-6993.
41. Franco-Bourland RE, Fernstrom JD. In vivo biosynthesis of L-[35S]Cys-arginine vasopressin, -oxytocin, and -somatostatin: rapid estimation using reversed phase high pressure liquid chro-matography. Endocrinology. 1981;109:1097-1106.
42. Ong GL, Miaskowski C, Haldar J. Changes in oxytocin and vaso-pressin content in posterior pituitary and hypothalamus following pantethine treatment. Life Sci. 1990;47:503-506.
43. Reichlin S, Bollinger-Gruber JA. Pantethine, a cysteamine precursor, depletes immunoreactive somatostatin and prolactin in the rat. Endocrinology. 1985;117:492-495.
44. Jeitner TM, Oliver JR. The depletion of plasma prolactin by pan-tethine in oestrogen-primed hyperprolactinaemic rats. J Endocrinol. 1990;124:397-402.
45. Jeitner TM, Oliver JR. Effect of cysteamine on the lysosomal enzymes of the hyperprolactinaemic rat pituitary. J Endocrinol. 1990;125:75-80.
46. Sellini M, Sartori M, Baccarini S, Bassi R. Various hormonal parameters (ACTH, cortisol, somatotropic hormone and prolac-tin). following administration of a single high dose of pantethine in healthy subjects (in Italian). Boll Soc Ital Biol Sper. 1987;63:143-145.
47. Rivera-Calimlim L, Hartley D, Osterhout D. Effect of ethanol and pantothenic acid on brain acetylcholine synthesis. Br J Pharmacol. 1988;95:77-82.
48. Abucham J, Bollinger-Gruber J, Reichlin S. Pantethine, a soma-tostatin depleting agent, increases food intake in rats. Pharmacol Biochem Behav. 1989;33:585-589.
49. Vecsei L, Alling C, Heilig M, Widerlov E. Effects of cysteamine and pantethine on open-field behavior, hypothalamic catecholamine concentrations, and somatostatin-induced barrel rotation in rats. Pharmacol Biochem Behav. 1989;32:629-635.
50. Vecsei L, Widerlov E, Ekman R, Alling C. Cysteamine and pantethine effects on passive avoidance behavior, shuttle box learning, open-field activity, striatal catecholamines and somatos-tatin. Arch Int Pharmacodyn Ther. 1989;299:14-27.
51. Vecsei L, Widerlov E. Preclinical and clinical studies with cystea-mine and pantethine related to the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:835-862.
52. Vecsei L, Widerlov E, Alling C. Effects of pantethine, cysteamine and pantothenic acid on open-field behavior and brain catechola-mines in rats. Arch Int Pharmacodyn Ther. 1989;300:14-21.
53. Vecsei L, Widerlov E, Alling C. Comparative studies of intracer-ebroventricularly administered cysteamine and pantethine in different behavioral tests and on brain catecholamines in rats. Arch Int Pharmacodyn Ther. 1990;305:140-151.
54. Vecsei L, Alling C, Heilig M, Widerlow E. Dose- and time-response effects of pantethine on open-field behavior, and on central neurotransmission in rats. Pharmacol Biochem Behav. 1990;35:165-170.
55. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002;8:143-149.
56. Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci. 2002;22:8942-8950.
57. Borrell-Pages M, Canals JM, Cordelieres FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006;116:1410-1424.
58. Tsai SJ. Cysteamine-related agents could be potential antidepres-sants through increasing central BDNF levels. Med Hypotheses. 2006;67:1185-1188.
59. Nagiel-Ostaszewski I, Lau-Cam CA. Protection by pantethine, pan-tothenic acid and cystamine against carbon tetrachloride-induced hepatotoxicity in the rat. Res Commun Chem Pathol Pharmacol. 1990;67:289-292.
60. Watanabe A, Hobara N, Kobayashi M, Nakatsukasa H, Nagashima H. Lowering of blood acetaldehyde but not ethanol concentrations by pantethine following alcohol ingestion: different effects in flushing and nonflushing subjects. Alcohol Clin Exp Res. 1985;9:272-276.
61. Watanabe A, Hobara N, Nagashima H. Activation and inhibition of yeast aldehyde dehydrogenase activity by pantethine and its metabolites. Ann Nutr Metab. 1986;30:54-57.
62. Orloff S, Butler JD, Towne D, Mukherjee AB, Schulman JD. Pan-tetheinase activity and cysteamine content in cystinotic and normal fibroblast and leukocytes. Pediatr Res. 1981;15:1063-1067.
63. Butler JD, Zatz M. Pantethine depletes cystinotic fibroblasts of cystine. J Pediatr. 1983;102:796-798.
64. Butler JD, Zatz M. Pantethine and cystamine deplete cystine from cystinotic fibroblasts via efflux of cysteamine-cystine mixed dis-ulfide. J Clin Invest. 1984;74:411-416.
65. Wittwer CT, Gahl WA, Butler JD, Zatz M, Thoene JG. Metabolism of pantethine in cystinosis. J Clin Invest. 1985;76:1665-1672.
66. Clark JI, Livesey JC, Steele JE. Delay or inhibition of rat lens opa-cification using pantethine and WR-77913. Exp Eye Res. 1996;62:75-84.
67. Hiraoka T, Clark JI, Li XY, Thurston GM. Effect of selected anti-cataract agents on opacification in the selenite cataract model. Exp Eye Res. 1996;62:11-19.
68. Congdon NT, West ST, Duncan DT, et al. The effect of pantethine and ultraviolet-B radiation on the development of lenticular opacity in the emory mouse. Curr Eye Res. 2000;20:17-24.
69. Penet MF, Abou-Hamdan M, Coltel N, et al. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci USA. 2008;105:1321-1326.